近日，总部位于中国的生物制药上市公司康方生物与 总部位于美国加利福尼亚的生物制药上市公司Summit Therapeutics Inc. 签署了一项交易总金额有望高达50亿美元合作许可协议。盛德律师事务所为康方生物提供了全程的法律服务。
据悉，康方生物将授权其突破性双特异性抗体ivonescimab在美国、加拿大、欧洲及日本市场的开发及商业化。
本次合作，康方生物将获得5亿美元预付款，潜在交易总价值还包括开发、注册和商业化里程碑款项付款可高达45亿美元。康方生物还将获得销售净额的低双位比例的提成作为ivonescimab 的特许专利使用费。
盛德团队由合伙人律师陆海波、Stephen Abreu、 Asher Rubin及主办律师王龙波率领。
Sidley Austin Represents Akeso in US$5 Billion Licensing Agreement With Summit Therapeutics
Sidley Austin is representing China based BioTech company Akeso Inc. in a high-profile US$5 billion collaboration and licensing agreement with the U.S. based BioTech company Summit Therapeutics Inc. to out-license its breakthrough bispecific antibody, ivonescimab, for development and commercialization in the U.S., Canada, Europe, and Japan.
Under the terms of the agreement, Akeso will receive a US$500 million upfront payment, with a total potential deal value of up to US$5 billion. Akeso will also receive a low double-digit percentage of royalties on net product sales of ivonescimab.
The Sidley team is led by partner James Lu, Stephen Abreu, Asher Rubin, and Wang Longbo.
